Sentence examples for treatment acquired from inspiring English sources

Suboptimal response is defined as follows: Atypical HUS: failure to correct thrombocytopenia and/or to improve renal function at day 5 of standard treatment Acquired TTP: PC not doubled by day 5 of standard treatment or diseaseprogression (increased thrombocytopenia or onset of organ damage) duringintensive first-line treatment or on reducing the frequency of PE (strong agreement).

When colonies were exposed to a range of Symbiodinium, only those colonies in the B224 treatment acquired the novel symbionts as detected using cp-23S-rDNA screening, indicating that only B224 was taken up in large numbers.

However, the efficacy of anti-HER2 therapeutics is restricted to a fraction of the patients, and even in those that initially respond to treatment, acquired resistance is commonly observed [8], [9].

Almost half of patients present baseline resistance (intrinsic resistance), and a large proportion of the remaining half will develop resistance during treatment (acquired resistance) [ 2].

The ΔCT values (for control and treatment) acquired from the qPCR were used to calculate the 2-ΔΔCT values to compare the results for different treatments.

However, many patients either do not respond to these therapies (de novo resistance) or develop resistance to them following prolonged treatment (acquired resistance).

Hookworm re-infection was low during the 16 weeks after the first treatment with only 10% of those pupils who were found uninfected after treatment acquiring new infections.

When ADF-null SCCs were depleted of CFL1 (siCFL1), the cells displayed altered morphology at 36 40 hr post-siRNA treatment, acquiring a flattened and more-spread phenotype with protrusions.

BIO-treated BAECs underwent dramatic morphological changes within 24 hours of treatment, acquiring a distinct mesenchymal appearance, whereas vehicle (i.e. DMSO -treated cells retaineDMSO -treatederisticellsblestone moretained of aorthe endothelial characteristic).

Indeed, human lymphomas derived from parental lines initially sensitive to ABT-737 treatment acquire resistance primarily through upregulation of Mcl-1 (and A1/Bfl-1).

In addition, variance in the first-line treatment of acquired CDI and its effect on treatment outcomes is unreported.